Panelists discuss the current treatment landscape of ES-SCLC, review recent clinical trials, and how they prepare their sites for tarlatamab administration, patient monitoring and management of adverse events Featured Video

Relacorilant and Nab-Paclitaxel Significantly Extend PFS in Ovarian Cancer
Data from the ROSELLA trial may support relacorilant plus nab-paclitaxel as a new treatment for patients with platinum-resistant ovarian cancer.

IMNN-001 May Show Enhanced Benefit in HRD-Positive Ovarian Cancer Subgroup
Future findings from a translational analysis of the OVATION-2 trial may corroborate prior clinical data for IMNN-001 in advanced ovarian cancer.

Zenocutuzumab is now approved for patients with NRG1 fusion-positive NSCLC or pancreatic adenocarcinoma.

  Featured Video

  Featured Video

SPC June Issue Online




www.specialtypharmacycontinuum.com/Digital-Issue/2024/June/4284?sub=872BD39D20AE39E0FDF9488EA5D47E8FD8DFEBA39CB0B315FB7FC3963DCB3E2D&enl=true&dgid=--DGID--&utm_source=enl&utm_content=0&utm_campaign=20240810&utm_medium=link